Alvotech specializes in the development and manufacturing of biosimilars through a vertically integrated process that includes cell line development and fill-finish manufacturing. This approach enhances access to affordable biologic medicines, addressing the high costs associated with traditional biologic therapies.
Funding
$965M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Biologic medicines are often expensive, limiting patient access despite their effectiveness in treating serious diseases. The high cost is due to the complex manufacturing processes and research required to develop these therapies.
Solution
Alvotech develops and manufactures biosimilars to increase access to more affordable biologic medicines. They employ a vertically integrated approach, managing the entire process from cell line development to fill-finish manufacturing. This strategy allows them to control quality, scale production, and accelerate the delivery of cost-competitive biosimilars to patients worldwide.
Target Audience
The primary target audience includes patients who require biologic medicines but are unable to afford current market prices, as well as healthcare providers and payers seeking cost-effective treatment options.
Features
- Vertically integrated manufacturing process from cell line development to fill-finish
- Focus on developing biosimilars of existing biologic medicines
- Pipeline of biosimilars targeting a range of therapeutic areas
- Strategic partnerships for commercialization and distribution
- Commitment to high-quality, cost-competitive manufacturing